| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PHAR.1426 |
| P698 | PubMed publication ID | 24753207 |
| P50 | author | Steven Gabardi | Q37830618 |
| P2093 | author name string | Miae Kim | |
| Spencer T Martin | |||
| Keri R Townsend | |||
| P2860 | cites work | OPTN/SRTR 2011 Annual Data Report: kidney | Q30581465 |
| Pharmacokinetics of intravenous immunoglobulin: a systematic review. | Q33371277 | ||
| Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria | Q33377654 | ||
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation | Q33392607 | ||
| Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients | Q33560520 | ||
| Adverse effects of intravenous immunoglobulin therapy | Q33733019 | ||
| Immunoglobulin in the control of complement action | Q34242612 | ||
| Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. | Q34659840 | ||
| Regulation of plasma-cell development | Q36058417 | ||
| Antibody-mediated organ-allograft rejection | Q36263023 | ||
| Antibody-mediated rejection in renal allografts: lessons from pathology | Q36910391 | ||
| Banff 2011 Meeting report: new concepts in antibody-mediated rejection | Q37058043 | ||
| The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. | Q37644840 | ||
| Antibody-mediated rejection in kidney transplantation: an update | Q37835834 | ||
| Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale | Q37990988 | ||
| The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature | Q38063607 | ||
| Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. | Q39716270 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. | Q40430473 | ||
| Summary of FDA antibody-mediated rejection workshop | Q42598786 | ||
| Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access | Q42968367 | ||
| Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report | Q43079825 | ||
| Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 | ||
| Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients | Q43705834 | ||
| Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects | Q43826723 | ||
| A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 | ||
| Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection | Q45061984 | ||
| Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 | ||
| Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience | Q46110628 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis | Q46549173 | ||
| Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients | Q46554252 | ||
| Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action | Q46681755 | ||
| National conference to assess antibody-mediated rejection in solid organ transplantation | Q47347260 | ||
| Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. | Q47862854 | ||
| Predicting kidney graft failure by HLA antibodies: a prospective trial. | Q51038562 | ||
| Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. | Q51333222 | ||
| Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. | Q53244973 | ||
| Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. | Q53388181 | ||
| Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. | Q54013696 | ||
| Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. | Q54146573 | ||
| "Hyperacute" renal-homograft rejection in man. | Q54626072 | ||
| Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 | ||
| Antibody-Mediated Rejection After Alemtuzumab Induction: Incidence, Risk Factors, and Predictors of Poor Outcome | Q58836886 | ||
| Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody | Q59230712 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| kidney transplantation | Q740909 | ||
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 733-744 | |
| P577 | publication date | 2014-04-19 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options | |
| P478 | volume | 34 |
| Q85813817 | A young man with persistent myalgia and fatigue: an off-label therapeutic approach |
| Q91814339 | Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study |
| Q38544529 | Advances in pharmacotherapy to treat kidney transplant rejection |
| Q37698860 | Antibody-Mediated Rejection: A Review |
| Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
| Q47094450 | Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients |
| Q38282840 | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection |
| Q93188012 | Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients |
| Q48955987 | De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis |
| Q47172094 | De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? |
| Q64263915 | Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff |
| Q53627040 | Eculizumab Salvage Therapy for Antibody-Mediated Rejection in a Desensitization-Resistant Intestinal Re-Transplant Patient. |
| Q35668667 | Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient |
| Q102058412 | Emergency Apheresis |
| Q36887183 | Expanding the antibody-mediated component of plasma cell-rich acute rejection: A case series |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q38644464 | Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. |
| Q49297064 | Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection |
| Q47378354 | Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. |
| Q49579181 | Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival |
| Q38967258 | Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement |
| Q38746225 | Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients |
| Q40417600 | Risk Evaluation and Outcome of Pneumocystis jirovecii Pneumonia in Kidney Transplant Patients. |
| Q92120680 | T Cell Subset Profile and Appearance of Donor-specific Antibodies in Primary and Retransplanted Kidney Recipients |
| Q38370826 | The need for minimization strategies: current problems of immunosuppression. |
| Q47311433 | Triptolide inhibits donor-specific antibody production and attenuates mixed antibody-mediated renal allograft injury. |
| Q38769922 | Use of polyclonal/monoclonal antibody therapies in transplantation |
Search more.